- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01219140
Pomegranate Extract Biomarker Study in Osteopenic Women
October 8, 2010 updated by: POM Wonderful LLC
A Randomized, Placebo-Controlled, Double-Blind, Parallel Design Trial to Evaluate the Safety and Efficacy of Pomegranate Extract Capsules in Post-Menopausal Subjects With Decreased Bone Mineral Density
Treatment of post-menopausal subjects (with decreased bone mineral density) with pomegranate extract capsules will produce statistically significant changes in biomarkers for bone resorption and formation when compared to subjects receiving placebo.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
64
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Florida
-
Miami, Florida, United States, 33126
- SeaView Research, Inc.
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
45 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Postmenopausal women (having had their last menstrual period within the past 15 years and an appropriate serum FSH value) 45-65 years of age;
- The subject must have a T score of -1 to -2.5 at the lumbar spine or proximal femur;
- All clinical safety laboratory values at screening and randomization must be either within the reference range or be determined by the investigator and the sponsor to be abnormal, but not clinically significant;
- The patient must have provided written informed consent.
Exclusion Criteria:
- The subject has any of the following conditions: connective tissue disease, history of clinically significant renal, hepatic pulmonary, cardiovascular, cerebrovascular, gastrointestinal, metabolic, hematological, endocrinological, urological, immunological, neurologic or psychiatric disorders, unless approved by the sponsor on a case by case basis;
- The subject has a positive test result for Hepatitis B surface antigen or antibody to hepatitis C virus at Screening;
- The subject has a known history of infection with the human immunodeficiency virus (HIV); -
- The subject has used bisphosphonate or fluoride therapy within the past 12 or 24 months, respectively;
- The subject has used denosumab within the past 24 months;
- The subject has used tibolone, parathyroid hormone (or any of its derivatives), systemic glucocorticoids or inhaled glucocorticoids, anabolic steroids or testosterone within the past 6 months;
- The subject has used estrogens, selective estrogen receptor modulators, calcitonin or calcitriol within the past 3 months;
- The subject has hyperparathyroidism, hypoparathyroidsim, hyperthyroidism, hypothyroidism, hypocalcemia, rheumatoid arthritis, paget's disease of bone, osteomalacia;
- The subject has had a bone fracture within the past year;
- The subject has acute or chronic disease requiring frequent changes in medications or dosages of chronic therapy;
- A history of alcoholism within the last 2 years or a current history of imbibing 3 or more units of alcohol per day. (1 unit is equivalent to 1 glass of wine, 1 pint of beer, or 1 shot of hard liquor);
- The subject has participated in another study with an investigational drug or device during the 30 days prior to study entry;
- The subject has a condition interfering with his ability to provide informed consent or comply with study instructions, or the patient has a condition, which might confound the interpretation of the study result;
- The subject has a condition endangering herself if she were to participate in this trial
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 2 POMx Capsules
2 POMx Capsules daily
|
2 POMx Capsules daily
|
Placebo Comparator: 2 placebo Capsules
2 placebo Capsules daily
|
2 placebo Capsules daily
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Biomarkers
Time Frame: Throughout study
|
To evaluate the impact of pomegranate extract capsules on urinary N-terminal telopeptide (NTX) and serum procollagen type 1 amino-terminal propeptide (P1NP), in post-menopausal women with decreased bone mineral density
|
Throughout study
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants with Adverse Events as a Measure of Safety and Tolerability
Time Frame: Throughout study
|
Incidence of adverse events Changes in vital signs or laboratory values
|
Throughout study
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2010
Primary Completion (Actual)
October 1, 2010
Study Completion (Actual)
October 1, 2010
Study Registration Dates
First Submitted
October 8, 2010
First Submitted That Met QC Criteria
October 8, 2010
First Posted (Estimate)
October 13, 2010
Study Record Updates
Last Update Posted (Estimate)
October 13, 2010
Last Update Submitted That Met QC Criteria
October 8, 2010
Last Verified
October 1, 2010
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- POM 2010-001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Osteopenic Women
-
Hospices Civils de LyonActive, not recruiting
-
Near East University, TurkeyCompletedHealthy Postmenopausal Women | Serum CNP Levels | Healthy Reproductive Age Women | Healthy Perimenopausal WomenCyprus
-
Universidad Peruana Cayetano HerediaCompleted
-
Halic UniversityCompletedWomen With Low Sexual Satisfaction | Partners of Women With Low Sexual SatisfactionTurkey
-
Atatürk UniversityCompleted
-
Cairo UniversityRecruitingPostmenopausal WomenEgypt
-
Ondokuz Mayıs UniversityRecruiting
-
Women's Hospital School Of Medicine Zhejiang UniversityRecruiting
-
Sultan Abdulhamid Han Training and Research Hospital...Not yet recruitingPregnant WomenTurkey
-
Fundacio d'Investigacio en Atencio Primaria Jordi...Institut Català de la Salut; Instituto de Salud Carlos IIINot yet recruiting
Clinical Trials on 2 POMx Capsules
-
POM Wonderful LLCTarget Health Inc.Completed
-
POM Wonderful LLCCompletedRecurrent Prostate CancerUnited States
-
HaEmek Medical Center, IsraelUnknown
-
University of California, Los AngelesCompleted
-
University of California, Los AngelesPOM Wonderful LLCCompleted
-
Loma Linda UniversityCompleted
-
Sancilio and Company, Inc.WithdrawnSevere Hypertriglyceridemia
-
POM Wonderful LLCCompleted
-
Jennifer Cowger , MD, MSPOM Wonderful LLCTerminatedHeart Failure | CardiomyopathyUnited States
-
University of California, Los AngelesCompletedCardiovascular Diseases